赛伦生物(688163) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 26,301,356.47, representing a year-on-year increase of 9.79%[4] - The net profit attributable to shareholders decreased by 51.09% to CNY 1,474,787.04[4] - Total operating revenue for Q1 2024 was CNY 26,301,356.47, an increase of 9.0% compared to CNY 23,955,839.36 in Q1 2023[19] - Net profit for Q1 2024 was CNY 1,474,787.04, a decrease of 51.0% from CNY 3,015,115.00 in Q1 2023[20] - The basic earnings per share (EPS) was CNY 0.01, down by 66.67% year-on-year[5] - Basic earnings per share for Q1 2024 were CNY 0.01, down from CNY 0.03 in Q1 2023[21] - The total comprehensive income for the period was 2,121,683.52 RMB, compared to 4,061,542.48 RMB in the previous year, reflecting a decrease in overall profitability[28] Research and Development - Research and development expenses totaled CNY 6,202,207.19, an increase of 89.35% compared to the previous year[5] - R&D expenses accounted for 23.58% of total revenue, up by 9.91 percentage points[5] - Research and development expenses increased to CNY 6,202,207.19 in Q1 2024, compared to CNY 3,275,505.96 in Q1 2023, representing an increase of 89.0%[19] - The company has not reported any new strategies or significant developments in product or technology during this quarter[12] Assets and Liabilities - The total assets at the end of the reporting period were CNY 1,122,965,626.39, a decrease of 0.49% from the end of the previous year[5] - The total current assets as of March 31, 2024, amounted to ¥940,355,041.14, a slight decrease from ¥948,930,376.53 as of December 31, 2023, reflecting a change of approximately -0.6%[15] - Total liabilities as of Q1 2024 amounted to CNY 35,650,233.88, down from CNY 42,631,940.16 in the previous period[18] - Current liabilities totaled CNY 17,848,273.13, a decrease of 28.5% from CNY 24,985,772.68[18] - The total assets as of March 31, 2024, were ¥1,122,965,626.39, down from ¥1,128,472,545.63, reflecting a decrease of approximately 0.5%[16] - The company reported accounts receivable of ¥38,499,090.20, an increase from ¥22,634,950.22, which is a significant rise of approximately 70%[16] - The total non-current assets amounted to ¥182,610,585.25, up from ¥179,542,169.10, indicating an increase of about 1.2%[16] Cash Flow - The net cash flow from operating activities was negative at CNY -21,796,451.38[4] - Cash inflow from operating activities was CNY 13,330,139.18 in Q1 2024, down from CNY 16,744,253.43 in Q1 2023, indicating a decline of 20.5%[21] - The net cash flow from operating activities for Q1 2024 was -21,796,451.38 RMB, compared to -18,617,864.27 RMB in Q1 2023, indicating a decline in operational cash flow[22] - The company reported a net cash outflow from investing activities of -5,046,128.03 RMB in Q1 2024, compared to -367,115,137.69 RMB in Q1 2023, indicating improved cash management[22] - The net cash flow from investment activities improved to 2,756,280.97 RMB, compared to a negative cash flow of -362,832,318.32 RMB in Q1 2023, showing a positive turnaround in investment performance[32] Government Support and Other Income - The company received government subsidies amounting to CNY 1,961,585.17 during the period[6] - The total non-recurring gains and losses amounted to CNY 7,272,094.99[7] Employee Compensation and Costs - The company paid 16,836,215.31 RMB in employee compensation during Q1 2024, an increase from 15,981,486.58 RMB in Q1 2023, indicating rising labor costs[31] - Total operating costs for Q1 2024 were CNY 28,345,641.29, up from CNY 24,097,126.11 in Q1 2023, reflecting a 17.0% increase[19] - The total cash outflow from operating activities was 41,441,864.04 RMB in Q1 2024, slightly higher than 40,267,406.20 RMB in Q1 2023, suggesting increased operational expenses[31] Shareholder Information - The company has no significant changes in the shareholding structure among the top shareholders, with the largest shareholder holding 34.05%[12] - There were no shares involved in the margin trading and securities lending business during the reporting period[13]